Global impact of rotavirus vaccines

  title={Global impact of rotavirus vaccines},
  author={Jacqueline e. Tate and Manish M Patel and Andrew Duncan Steele and Jon R. Gentsch and Daniel C. Payne and Margaret M Cortese and Osamu Nakagomi and Nigel A. Cunliffe and Baoming Jiang and Kathleen M. Neuzil and L{\'u}cia Helena de Oliveira and Roger I Glass and Umesh D. Parashar},
  journal={Expert Review of Vaccines},
  pages={395 - 407}
The WHO has recently recommended the inclusion of rotavirus vaccine in the national immunization programs of all countries. In countries in the Americas, Europe and Australia that have adopted routine childhood immunization against rotavirus, significant reductions in the burden of severe childhood diarrhea have been observed. Besides protecting vaccinated children, disease rates also appear to be reduced in unvaccinated children, suggesting indirect benefits from vaccination (i.e., herd… 
Rotavirus vaccines
The epidemiology of rotavirus disease, the development and current status ofRotavirus vaccines including newly available vaccine impact data from early-introducer countries, and future priorities for implementation and monitoring of rotvirus vaccination programs in developing countries are reviewed.
Effectiveness of pneumococcal conjugate vaccine and rotavirus vaccine introduction into the South African public immunisation programme.
The rationale for and process of the introduction of these two vaccines, pneumococcal conjugate vaccine and rotavirus vaccine, are described and the success of and challenges related to their introduction are evaluated, in terms of both achieving universal coverage and improving survival and health in South African children.
Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines
Should rotavirus vaccines be introduced in the routine immunization programs of all countries, a potential of 170,000 deaths could be prevented annually, despite poor immunization coverage and lower efficacy.
[Toward the elimination of rotavirus gastroenteritis by universal vaccination].
Countries where either rotavirus vaccination of infants was introduced into the national childhood immunization program have witnessed not only a drastic decrease in the number of rotav virus hospitalizations but a near 50% reduction in theNumber of all-cause-diarrhea hospitalizations.
Progress in the Introduction of the Rotavirus Vaccine in Latin America and the Caribbean: Four Years of Accumulated Experience
Rotavirus vaccine introduction in Latin American and Caribbean (LAC) countries has been faster than for other new vaccines, but coverage levels need to increase to maximize the effect of the intervention.
New approaches in oral rotavirus vaccines
Development of new oral rotavirus vaccine classes – live-attenuated vaccines, virus-like particles, lactic acid bacteria-containing vaccines, combination therapy with immunoglobulins, and biodegradable polymer-encapsulated vaccines – could potentially circumvent problems of the reduced efficacy of the existing rotaviral vaccines in developing countries over time.
Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review
This article provides a review of the product profile of the Rotarix vaccine for use in the national immunisation programme in the UK from an expert perspective and concludes that this single G1P[8] strain-based human rotavirus vaccine has demonstrated high efficacy in preventing severe rotav virus gastroenteritis in the first 3 years of life in middle- and high-income countries.
Rotavirus vaccines: a story of success.
Epidemiology and prospects for prevention of rotavirus disease in India
The epidemiology and burden of rotav virus diarrhea is fairly well characterized in India, and introducing rotavirus vaccine into the UIP should be an important part of efforts to reduce diarrhea mortality, the third leading cause of death among Indian children, and achieve the country’s MDG goals.
Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi
It is found that vaccine effectiveness during the first and second years of life could potentially be improved by increasing the proportion of infants who respond to vaccination or by lowering the rotavirus transmission rate.


Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
Data is reviewed for the protective efficacy of the 2 new rotavirus vaccines, with emphasis on issues particularly important for consideration as these vaccines are introduced in routine infant immunization programs.
Oral rotavirus vaccines: how well will they work where they are needed most?
Although introduction today of even moderately effective vaccines will decrease the morbidity and mortality associated with rotavirus in low-income settings, research is urgently needed to understand why differences in efficacy occur and what could be done to improve vaccine performance to maximize the life-saving benefits of vaccination.
Rotavirus vaccines: targeting the developing world.
For the global effort toward the prevention of rotavirus disease to be successful, special efforts will be required in India, China, and Indonesia, because one-third of all deaths due to rotav virus disease occur in these countries, and because these countries depend almost entirely on vaccines manufactured domestically.
Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
The Advisory Committee on Immunization Practices recommends routine vaccination of U.S. infants with 3 doses of this rotavirus vaccine administered orally at ages 2, 4, and 6 months.
Withdrawal of rotavirus vaccine recommendation.
  • Medicine
    MMWR. Morbidity and mortality weekly report
  • 1999
In July 1999, CDC recommended that health-care providers and parents postpone use of the rhesus rotavirus vaccine-tetravalent (RRV-TV) (RotaShield, Wyeth Laboratories, Inc., Marietta, Pennsylvania),
A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis
Results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation.